Patent ID: 7195750
Filing Date: 2007-03-27
Classification: A61K,A61P,C07K,G01N

Abstract:
1. A method for reduction of hernatologic toxicity resulting from administration of a radiolabeled antibody to a cancer patient having bone marrow involvement, the method comprising: (a) administering a therapeutically effective amount of non-labeled depleting antibody selected from the group consisting of anti-CD19, anti-CD20 and anti-CD22 antibodies that such that said bone marrow involvement is decreased below the initial degree of bone marrow involvement; and (b) administering a therapeutic radiolabeled antibody selected from the group consisting of anti-CD19, anti-CD20 and anti-CD22 antibodies while said bone marrow involvement is decreased below the initial degree of bone marrow involvement; said method being performed without prior imaging or dosimetry.